{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:58:42Z","timestamp":1758045522013,"version":"3.44.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.amjms.2020.11.012","type":"journal-article","created":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T09:56:29Z","timestamp":1606038989000},"page":"526-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A 65-year-old Woman With Persistent Dyspnea, Arthritis, and Raynaud's Phenomenon"],"prefix":"10.1016","volume":"361","author":[{"given":"Woon H.","family":"Chong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biplab K.","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Beegle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.amjms.2020.11.012_bib0001","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.amjms.2020.11.012_bib0002","doi-asserted-by":"crossref","unstructured":"Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011; 37(1):100-9.","DOI":"10.1590\/S1806-37132011000100015"},{"issue":"32","key":"10.1016\/j.amjms.2020.11.012_bib0003","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical spectrum time course in Anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.amjms.2020.11.012_bib0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1183\/09031936.00060107","article-title":"Occult connective tissue diseases mimicking idiopathic interstitial pneumonias","volume":"31","author":"Tzelepis","year":"2008","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.amjms.2020.11.012_bib0005","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1378\/chest.12-0741","article-title":"Diagnosis and treatment of connective tissue disease-associated interstitial lung disease","volume":"143","author":"Vij","year":"2013","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.amjms.2020.11.012_bib0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/jcm6050051","article-title":"Role of Autoantibodies in the diagnosis of connective-tissue Disease ILD (CTD-ILD) and interstitial pneumonia with autoimmune features (IPAF)","volume":"6","author":"Jee","year":"2017","journal-title":"JCM"},{"issue":"5","key":"10.1016\/j.amjms.2020.11.012_bib0007","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CPM.0000000000000171","article-title":"The diagnosis and treatment of antisynthetase syndrome","volume":"23","author":"Witt","year":"2016","journal-title":"Clin Pulmonary Med"},{"issue":"2","key":"10.1016\/j.amjms.2020.11.012_bib0008","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/157339710791330740","article-title":"Interstitial lung disease in idiopathic inflammatory myopathy","volume":"6","author":"Saketkoo","year":"2010","journal-title":"CRR"},{"issue":"9","key":"10.1016\/j.amjms.2020.11.012_bib0009","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/art.22865","article-title":"Anti\u2013Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy","volume":"56","author":"Stone","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.amjms.2020.11.012_bib0010","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3899\/jrheum.120682","article-title":"Diagnosis, and management of idiopathic inflammatory myopathies","volume":"40","author":"Lazarou","year":"2013","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.amjms.2020.11.012_bib0011","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/BOR.0b013e3282f01a8c","article-title":"Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance","volume":"19","author":"Mimori","year":"2007","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.amjms.2020.11.012_bib0012","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","article-title":"Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression","volume":"48","author":"Gunawardena","year":"2009","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.amjms.2020.11.012_bib0013","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/ar1862","article-title":"In adult onset myositis, the presence of interstitial lung disease and myositis specific\/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype","volume":"8","author":"Chinoy","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.amjms.2020.11.012_bib0014","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.bbadis.2014.05.034","article-title":"Dermatomyositis, polymyositis and immune-mediated necrotising myopathies","volume":"1852","author":"Luo","year":"2015","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"issue":"2","key":"10.1016\/j.amjms.2020.11.012_bib0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00300245","article-title":"Coxsackievirus infection and the development of polymyositis\/dermatomyositis","volume":"14","author":"Nishikai","year":"1994","journal-title":"Rheumatol Int"},{"issue":"24","key":"10.1016\/j.amjms.2020.11.012_bib0016","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1073\/pnas.87.24.9933","article-title":"The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity","volume":"87","author":"Miller","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.amjms.2020.11.012_bib0017","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20020186","article-title":"Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells","volume":"196","author":"Howard","year":"2002","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.amjms.2020.11.012_bib0018","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1002\/art.22790","article-title":"Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis","volume":"56","author":"Levine","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.amjms.2020.11.012_bib0019","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","article-title":"Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy","volume":"201","author":"Casciola-Rosen","year":"2005","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.amjms.2020.11.012_bib0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1378\/chest.15-1145","article-title":"Clinical characteristics of connective tissue disease-associated interstitial lung disease in 1,044 Chinese patients","volume":"149","author":"Hu","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.amjms.2020.11.012_bib0021","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.amjms.2020.11.012_bib0022","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/ard.2003.006122","article-title":"Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis","volume":"63","author":"Fathi","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjms.2020.11.012_bib0023","unstructured":"Chapman JR, Charles PJ, Venables PJ, et al. Definition and clinical relevance of antibodies to nuclear ribonucleoprotein and other nuclear antigens in patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis. 1984;130(3):439-43."},{"issue":"5","key":"10.1016\/j.amjms.2020.11.012_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/jcp.54.5.413","article-title":"Is it useful to test for antibodies to extractable nuclear antigens in the presence of a negative antinuclear antibody on Hep-2 cells","volume":"54","author":"Thomson","year":"2001","journal-title":"J Clin Pathol"},{"issue":"6","key":"10.1016\/j.amjms.2020.11.012_bib0025","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10067-004-0937-0","article-title":"Utility of age, gender, ANA titer and pattern as predictors of anti-ENA and -dsDNA antibodies","volume":"23","author":"Kang","year":"2004","journal-title":"Clin Rheumatol"},{"issue":"4-5","key":"10.1016\/j.amjms.2020.11.012_bib0026","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.autrev.2014.01.022","article-title":"Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review","volume":"13","author":"Mahler","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.amjms.2020.11.012_bib0027","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.amjms.2020.11.012_bib0028","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/jaut.1998.0265","article-title":"The association of Anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies","volume":"12","author":"Frank","year":"1999","journal-title":"J Autoimmun"},{"key":"10.1016\/j.amjms.2020.11.012_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2012\/415272","article-title":"Anti-Ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma","volume":"2012","author":"Ferreira","year":"2012","journal-title":"ISRN Rheumatol"},{"issue":"9","key":"10.1016\/j.amjms.2020.11.012_bib0030","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00296-009-0884-9","article-title":"Characteristics of interstitial lung disease in SS-A positive\/Jo-1 positive inflammatory myopathy patients","volume":"29","author":"V\u00e1ncsa","year":"2009","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.amjms.2020.11.012_bib0031","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.amjms.2020.11.012_bib0032","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1016\/j.amjms.2020.11.012_bib0033","doi-asserted-by":"crossref","DOI":"10.1080\/20018525.2019.1583516","article-title":"Clinical characteristics and outcome in patients with antisynthetase syndrome associated interstitial lung disease: a retrospective cohort study","volume":"6","author":"Jensen","year":"2019","journal-title":"Eur Clin Respir J"},{"issue":"5","key":"10.1016\/j.amjms.2020.11.012_bib0034","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MAJ.0b013e31818d094b","article-title":"Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects","volume":"337","author":"Saketkoo","year":"2009","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.amjms.2020.11.012_bib0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.amjms.2020.11.012_bib0036","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/s10165-007-0553-3","article-title":"Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis\/polymyositis: a retrospective study","volume":"17","author":"Takada","year":"2007","journal-title":"Mod Rheumatol"},{"issue":"8","key":"10.1016\/j.amjms.2020.11.012_bib0037","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.amjms.2020.11.012_bib0038","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","article-title":"Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome","volume":"106","author":"Marie","year":"2012","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.amjms.2020.11.012_bib0039","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/rheumatology\/kew195","article-title":"Rituximab in autoimmune connective tissue disease-associated interstitial lung disease","volume":"55","author":"Sharp","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.amjms.2020.11.012_bib0040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.amjms.2020.11.012_bib0041","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0002-9343(90)90149-8","article-title":"Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase)","volume":"88","author":"Targoff","year":"1990","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.amjms.2020.11.012_bib0042","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/art.1780350718","article-title":"Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease","volume":"35","author":"Targoff","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.amjms.2020.11.012_bib0043","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.4049\/jimmunol.144.5.1737","article-title":"Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis","volume":"144","author":"Targoff","year":"1990","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.amjms.2020.11.012_bib0044","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel435","article-title":"Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies","volume":"46","author":"Sato","year":"2007","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.amjms.2020.11.012_bib0045","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/art.22506","article-title":"Clinical and immunogenetic features of patients with autoantibodies to asparaginyl\u2013transfer RNA synthetase","volume":"56","author":"Hirakata","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.amjms.2020.11.012_bib0046","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kem045","article-title":"Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia","volume":"46","author":"Betteridge","year":"2007","journal-title":"Rheumatology"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962920305000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962920305000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:38:11Z","timestamp":1757702291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962920305000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0002962920305000"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2020.11.012","relation":{},"ISSN":["0002-9629"],"issn-type":[{"type":"print","value":"0002-9629"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 65-year-old Woman With Persistent Dyspnea, Arthritis, and Raynaud's Phenomenon","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2020.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}